Coherus' Toripalimab/Chemo Combo Cuts Death Risk By 37% In Nasopharyngeal Cancer Patients
Portfolio Pulse from Vandana Singh
Coherus BioSciences announced the final overall survival results of the JUPITER-02 Phase 3 study of toripalimab in combination with gemcitabine and cisplatin as a first-line treatment for nasopharyngeal carcinoma. The treatment resulted in a 37% reduction in the risk of death compared to chemotherapy alone. The FDA is currently reviewing the Biologics License Application for toripalimab, with potential approval in Q3 2023.
June 06, 2023 | 3:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Coherus BioSciences' toripalimab/chemo combo shows promising results in reducing death risk for nasopharyngeal cancer patients. FDA is reviewing the application, with potential approval in Q3 2023.
The positive results from the JUPITER-02 Phase 3 study show a significant improvement in overall survival for patients treated with toripalimab combined with chemotherapy. This could lead to increased demand for the treatment and potential revenue growth for Coherus BioSciences. The FDA's ongoing review of the Biologics License Application and potential approval in Q3 2023 could further boost the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100